More Good News For Bayer's Larotrectinib Ahead Of FDA Verdict
An update on Bayer and Loxo's tissue-agnostic therapy for cancers with NTRK gene fusions has impressed, confirming the sustained durable effect of larotrectinib as it nears its action date for approval in the US.
You may also be interested in...
The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.
AbbVie faces analysts just a couple weeks after Humira biosimilars hit the market, and with Gilead launching authorized generics of its hepatitis C combos, the TNF franchise is not the only one under attack at AbbVie. Investors are keen to see AstraZeneca start its turnaround to growth, while Lilly is looking to a strong future based on new diabetes data and Bayer braces for a new push in oncology.
Pricing pressure and difficulties with market access in competitive classes will be common themes as Teva, Novo Nordisk and Shire report third quarter sales and earnings.